FIRDAPSE (amifampridine)
Lambert-Eaton Myasthenic Syndrome (LEMS)
Key Facts
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals has successfully transitioned from a development-stage entity to a profitable commercial organization focused on rare neuromuscular and neurological diseases. Its strategy centers on acquiring or in-licensing late-stage/commercial assets, maximizing lifecycle value, and maintaining an intense patient-first operational culture. This approach has yielded a marketed portfolio, a growing pipeline, and recognition as a top small-cap company, positioning it for continued growth in specialized therapeutic areas.
View full company profileAbout Catalyst Pharmaceuticals
Catalyst Pharmaceuticals has successfully transitioned from a development-stage entity to a profitable commercial organization focused on rare neuromuscular and neurological diseases. Its strategy centers on acquiring or in-licensing late-stage/commercial assets, maximizing lifecycle value, and maintaining an intense patient-first operational culture. This approach has yielded a marketed portfolio, a growing pipeline, and recognition as a top small-cap company, positioning it for continued growth in specialized therapeutic areas.
View full company profileTherapeutic Areas
Other Lambert-Eaton Myasthenic Syndrome (LEMS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Firdapse® (amifampridine phosphate) | Dydo Pharma | Approved |